ARTICLE | Deals
Plus: Gilead acquires Xilio’s IL-12 program and Harmonic-Turbine to co-develop dark kinase therapy for cancer
By Gunjan Ohri, Data Content Analyst
April 2, 2024 2:08 AM UTC
Two PE firms made risk-sharing investments in late-stage programs this week.
After closing a $356 million fund in October to support development of largely de-risked programs, Abingworth committed up to $150 million to late-stage asthma therapy TEV-’248 from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA), in return for fixed payments and sales milestones. Abingworth-backed Launch Therapeutics Inc. agreed to lead the Phase III trials of the dual-action rescue inhaler. Teva will be responsible for manufacturing and regulatory affairs in the U.S. and commercialization. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651961/deals-report-abingworth-and-blackstone-bet-on-late-stage-programs